Compositions and methods for the treatment and diagnosis of immune disorders

A monoclonal antibody or fragment thereof which binds to:

• a) the amino acid sequence of SEQ ID NO:10 or SEQ ID NO:24, or the amino acid sequence encoded by the cDNA insert of the clone contained within ATCC Accession Number 69967, NRRL Accession Number B-21395, NRRL Accession Number B-21416, or NRRL Accession Number B-21457;
• b) amino acid residues 1-20, 1-200, 1-224, 30-128, 21-200, 21-224, 21-301, 201-224, 201-301 or 225-301 of SEQ ID NO:24;
• or
• c) amino acid residues 1-20, 1-192, 1-214, 21-192, 21-214, 21-281, 193-214, 215-281 or 215-281 of SEQ ID NO:10.

A humanized antibody or fragment thereof which binds to:

• a) the amino acid sequence of SEQ ID NO:10 or SEQ ID NO:24, or the amino acid sequence encoded by the cDNA insert of the clone contained within ATCC Accession Number 69967, NRRL Accession Number B-21395, NRRL Accession Number B-21416, or NRRL Accession Number B-21457;
• b) amino acid residues 1-20, 1-200, 1-224, 30-128, 21-200, 21-224, 21-301, 201-224, 201-301 or 225-301 of SEQ ID NO:24;
• or
• c) amino acid residues 1-20, 1-192, 1-214, 21-192, 21-214, 21-281, 193-214, 215-281 or 215-281 of SEQ ID NO:10.

An antibody Fc region fusion polypeptide comprising an antibody Fc region linked to:

• a) the amino acid sequence of SEQ ID NO:10 or SEQ ID NO:24, or the amino acid sequence encoded by the cDNA insert of the clone contained within ATCC Accession Number 69967, NRRL Accession Number B-21395, NRRL Accession Number B-21416, or NRRL Accession Number B-21457;
• b) amino acid residues 1-20, 1-200, 1-224, 30-128, 21-200, 21-224, 21-301, 201-224, 201-301 or 225-301 of SEQ ID NO:24;
• or
• c) amino acid residues 1-20, 1-192, 1-214, 21-192, 21-214, 21-281, 193-214, 215-281 or 215-281 of SEQ ID NO:10.

An isolated antibody or fragment thereof which binds to a 200 gene product differentially expressed on Th1 cells, wherein the 200 gene product comprises and the antibody binds to:

• a) the amino acid sequence of SEQ ID NO:10 or SEQ ID NO:24, or the amino acid sequence encoded by the cDNA insert of the clone contained within ATCC Accession Number 69967, NRRL Accession Number B-21395, NRRL Accession Number B-21416, or NRRL Accession Number B-21457;
• b) amino acid residues 1-20, 1-200, 1-224, 30-128, 21-200, 21-224, 21-301, 201-224, 201-301 or 225-301 of SEQ ID NO:24;
• or
• c) amino acid residues 1-20, 1-192, 1-214, 21-192, 21-214, 21-281, 193-214, 215-281 or 215-281 of SEQ ID NO:10.

A monoclonal antibody or fragment thereof which binds to a 200 gene product differentially expressed on Th1 cells, wherein the 200 gene product comprises and the antibody binds to:

• a) the amino acid sequence of SEQ ID NO:10 or SEQ ID NO:24, or the amino acid sequence encoded by the cDNA insert of the clone contained within ATCC Accession Number 69967, NRRL Accession Number B-21395, NRRL Accession Number B-21416, or NRRL Accession Number B-21457;
• b) amino acid residues 1-20, 1-200, 1-224, 30-128, 21-200, 21-224, 21-301, 201-224, 201-301 or 225-301 of SEQ ID NO:24;
• or
• c) amino acid residues 1-20, 1-192, 1-214, 21-192, 21-214, 21-281, 193-214, 215-281 or215-281 of SEQ ID NO:10.

A humanized antibody or fragment thereof which binds to a 200 gene product differentially expressed on Th1 cells, wherein the 200 gene product comprises and the antibody binds to:

• a) the amino acid sequence of SEQ ID NO:10 or SEQ ID NO:24, or the amino acid sequence encoded by the cDNA insert of the clone contained within ATCC Accession Number 69967, NRRL Accession Number B-21395, NRRL Accession Number B-21416, or NRRL Accession Number B-21457;
• b) amino acid residues 1-20, 1-200, 1-224, 30-128, 21-200, 21-224, 21-301, 201-224, 201-301 or 225-301 of SEQ ID NO:24;
• or
• c) amino acid residues 1-20, 1-192, 1-214, 21-192, 21-214, 21-281, 193-214, 215-281 or 215-281 of SEQ ID NO:10.